WO2023246777A1 - Inhibiteurs de protéine mutante k-ras - Google Patents

Inhibiteurs de protéine mutante k-ras Download PDF

Info

Publication number
WO2023246777A1
WO2023246777A1 PCT/CN2023/101393 CN2023101393W WO2023246777A1 WO 2023246777 A1 WO2023246777 A1 WO 2023246777A1 CN 2023101393 W CN2023101393 W CN 2023101393W WO 2023246777 A1 WO2023246777 A1 WO 2023246777A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
membered
haloc
stereoisomer
alkynyl
Prior art date
Application number
PCT/CN2023/101393
Other languages
English (en)
Inventor
Hongwei Yang
Cunbo Ma
Peng Wang
Panliang GAO
Huifeng HAN
Runze LI
Dan Liu
Yanping Wang
Wei LONG
Original Assignee
Jacobio Pharmaceuticals Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jacobio Pharmaceuticals Co., Ltd. filed Critical Jacobio Pharmaceuticals Co., Ltd.
Publication of WO2023246777A1 publication Critical patent/WO2023246777A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the invention relates to compounds that inhibit the activity of multiple forms of K-Ras protein including K-Ras wild type and K-Ras mutant types, compositions comprising the same, and the methods of using the same.
  • K-Ras Kirsten Rat Sarcoma 2 Viral Oncogene Homolog
  • GDP-bound inactive
  • GTP-bound active
  • Aberrant expression of K-Ras accounts for up to ⁇ 20%of all cancers and oncogenic K-Ras mutations that stabilize GTP binding and lead to constitutive activation of K-Ras.
  • K-Ras mutations at codons 12, 13, 61 and other positions of the K-Ras primary amino acid sequence are present in 88%of all pancreatic adenocarcinoma patients, 50%of all colorectal adenocarcinoma patients, and 32%lung adenocarcinoma patients.
  • a recent publication also suggested wild type K-Ras inhibition could be a viable therapeutic strategy to treat K-Ras wild type dependent cancers.
  • Allele-specific K-Ras G12C inhibitors such as sotorasib (AMG510) or adagrasib (MRTX849) , are currently changing the treatment paradigm for patients with K-Ras G12C mutated non-small cell lung cancer and colorectal cancer.
  • sotorasib AMG510
  • MRTX849 adagrasib
  • a compound of formula (I) or formula (II) a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof, a prodrug thereof, a deuterated molecule thereof or a conjugated form thereof:
  • Also provided herein is a method for treating cancer in a subject comprising administering a therapeutically effective amount of a compound of formula (I) or formula (II) , a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof, a prodrug thereof, a deuterated molecule thereof, a PROTAC molecule thereof, or a pharmaceutical composition as defined herein to a subject in need thereof.
  • X 2 at each occurrence is independently selected from N or CR 1 ;
  • R 2 is selected from hydrogen, deuterium, -C 1-10 alkyl, haloC 1-10 alkyl, haloC 1-10 alkoxy, -C 2-10 alkenyl, haloC 2-10 alkenyl, -C 2-10 alkynyl, haloC 2-10 alkynyl, -N (R A ) 2 , -OR A , -SR A , 3-10 membered cycloalkyl, 3-10 membered cycloalkenyl, 3-10 membered cycloalkynyl, 3-10 membered heterocyclyl, 6-10 membered aryl or 5-10 membered heteroaryl; wherein said -C 1-10 alkyl, haloC 1-10 alkyl, haloC 1-10 alkoxy, -C 2-10 alkenyl, -C 2-10 alkynyl, 3-10 membered cycloalkyl, 3-10 membered cycloalkenyl, 3-10
  • two R S1 together with the carbon atom to which they are both attached form a 3-10 membered carbocyclic ring or a 3-10 heterocyclic ring; wherein, said 3-10 discharged carbocylic ring or 3-10 heterocyclic ring is independently unsubstituted or substituted with one or more R S11 ;
  • R S1 together with the atoms to which they are respectively attached form a 3-10 membered carbocyclic ring, a 3-10 membered heterocyclic ring, a 6-10 membered aryl ring or a 5-10 membered heteroaryl ring, wherein, each of rings is independently unsubstituted or substituted with one or more R S12 ;
  • n 1 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9;
  • R 33 and R 34 together with the carbon atom to which they are both attached form a 3-10 membered carbocyclic ring or a 3-10 heterocyclic ring; wherein, said 3-10 discharged carbocylic ring or 3-10 heterocyclic ring is independently unsubstituted or substitutedwith one or more R S34 ;
  • R 35 and R 36 together with the carbon atom to which they are both attached form a 3-10 membered carbocyclic ring or a 3-10 heterocyclic ring; wherein, said 3-10 discharged carbocylic ring or 3-10 heterocyclic ring is independently unsubstituted or substituted with one or more R S35 ;
  • R 38 and R 39 together with the carbon atom to which they are both attached form a 3-10 membered carbocyclic ring or a 3-10 heterocyclic ring; wherein, said 3-10 discharged carbocylic ring or 3-10 heterocyclic ring is independently unsubstituted or substituted with one or more R S310 ;
  • n 2 is selected from 0, 1, 2, 3, 4, 5 or 6;
  • n 4 is selected from 0, 1, 2, 3, 4, 5 or 6;
  • n 6 is selected from 0, 1, 2, 3, 4, 5 or 6;
  • two R S31 together with the carbon atom to which they are both attached form a 3-10 membered carbocyclic ring or a 3-10 membered heterocyclic ring; wherein, said 3-10 discharged carbocylic ring or 3-10 heterocyclic ring is independently unsubstituted or substituted with one or more R S311 ;
  • m 3 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12;
  • two R S32 together with the carbon atom to which they are both attached form a 3-10 membered carbocyclic ring or a 3-10 heterocyclic ring; wherein, said 3-10 discharged carbocylic ring or 3-10 heterocyclic ring is independently unsubstituted or substituted with one or more R S321 ;
  • R S32 together with the carbon atoms to which they are respectively attached form a 3-10 membered carbocyclic ring, a 3-10 membered heterocyclic ring, a 6-10 membered aryl ring or a 5-10 membered heteroaryl ring, wherein, each of rings is independently unsubstituted or substituted with one or more R S322 ;
  • n 4 is selected from 0, 1, 2, 3, 4, 5 or 6;
  • R 37 is selected from -N (R 37A ) 2 or 3-10 membered heterocyclyl, wherein said 3-10 membered heterocyclyl is optionally independently substituted with one or more R S37 ;
  • two R S38 together with the carbon atom to which they are both attached form a 3-10 membered carbocyclic ring or a 3-10 membered heterocyclic ring; wherein, said 3-10 discharged carbocylic ring or 3-10 heterocyclic ring is independently unsubstituted or substituted with one or more R S381 ;
  • R S38 together with the carbon atoms to which they are respectively attached form a 3-10 membered carbocyclic ring, a 3-10 membered heterocyclic ring, a 6-10 membered aryl ring or a 5-10 membered heteroaryl ring, wherein, each of rings is independently unsubstituted or substituted with one or more R S382 ;
  • n 8 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12;
  • two R S39 together with the carbon atom to which they are both attached form a 3-10 membered carbocyclic ring or a 3-10 heterocyclic ring; wherein, said 3-10 discharged carbocylic ring or 3-10 heterocyclic ring is independently unsubstituted or substituted with one or more R S391 ;
  • R S39 together with the carbon atoms to which they are respectively attached form a 3-10 membered carbocyclic ring, a 3-10 membered heterocyclic ring, a 6-10 membered aryl ring or a 5-10 membered heteroaryl ring, wherein, each of rings is independently unsubstituted or substituted with one or more R S392 ;
  • n 9 is selected from 0, 1, 2, 3, 4, 5 or 6;
  • two R S315 together with the carbon atom to which they are both attached form a 3-10 membered carbocyclic ring or a 3-10 heterocyclic ring; wherein, said 3-10 discharged carbocylic ring or 3-10 heterocyclic ring is independently unsubstituted or substituted with one or more R S3151 ;
  • n 10 is selected from 0, 1, 2, 3, 4, 5 or 6;
  • Ring E at each occurrence is independently selected from a 6 membered aryl ring or a 5-6 membered heteroaryl ring and ring F at each occurrence is a 3-10 membered carbocyclic ring or a 3-10 membered heterocyclic ring when Z is selected from C;
  • Ring E at each occurrence is selected from a 5-6 membered heteroaryl ring and ring F at each occurrence is a 3-10 membered heterocyclic ring when Z is selected from N;
  • R 1B , R 1D , R S1B , R S1D , R S31B , R S31D , R S32B , R S32D , R S38B , R S38D , R S39B , R S315B , R S315D , R S39D , R S4B , R S4D , R 5B , R 5D , R 6B , and R 6D is independently selected from hydrogen, deuterium, -C 1-6 alkyl, haloC 1-6 alkyl, haloC 1-6 alkoxy, -C 2-6 alkenyl, haloC 2-6 alkenyl, -C 2-6 alkynyl, haloC 2-6 alkynyl, -N (R A ) 2 , -OR A , -SR A , 3-10 membered cycloalkyl, 3-10 membered cycloalkenyl, 3-10 membered cycl
  • R S11 , R S12 , R S13 , R S33 , R S34 , R S35 , R S37 , R S310 , R S316 , R S311 , R S312 , R S313 , R S321 , R S322 , R S323 , R S381 , R S382 , R S383 , R S391 , R S392 , R S393 , R S3151 , R S3152 , R S3153 , R SS and R SA is independently selected from deuterium, halogen, -C 1-6 alkyl, haloC 1-6 alkyl, haloC 1-6 alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl, -CN, -NO 2 , -N 3 , oxo, -NH 2 , -NH(C 1-6 alkyl) , -N (C 1-6 alkyl
  • Each of heteroaryl at each occurrence independently contains 1, 2, 3 or 4 heteroatoms selected from N, O, or S.
  • R S2 is same as R S1 ;
  • R S1 is selected from halogen or -C 1-6 alkyl; wherein said -C 1-6 alkyl is independently unsubstituted or substituted with 1, 2, or 3 substituents selected from deuterium, halogen, haloC 1-6 alkyl, haloC 1-6 alkoxy, -CN, -NH 2 , -NH (C 1-6 alkyl) , -N (C 1-6 alkyl) 2 , -OH or -OC 1-6 alkly;
  • two adjacent R S1 together with the atoms to which they are respectively attached form a 3-6 membered carbocyclic ring, a 3-6 membered heterocyclic ring, a phenyl ring or a 5-6 membered heteroaryl ring, wherein, each of rings is independently unsubstituted or substituted with 1, 2, or 3 substituents slected from deuterium, halogen, haloC 1-6 alkyl, haloC 1-6 alkoxy, -CN, -NH 2 , -NH (C 1-6 alkyl) , -N (C 1-6 alkyl) 2 , -OH or -OC 1-6 alkly.
  • a compound of formula (II) a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer, a prodrug thereof, a deuterated molecule thereof or a PROTAC molecule thereof:
  • X 2 at each occurrence is independently selected from N or CR 1 ;
  • R 81 and R 82 together with the carbon atom to which they are both attached form a 3-10 membered carbocyclic ring or a 3-10 heterocyclic ring; wherein, said 3-10 discharged carbocylic ring or 3-10 heterocyclic ring is independently unsubstituted or substituted with one or more R S81 ;
  • R 81 and R S8 together with the atoms to which they are respectively attached form a 3-10 membered carbocyclic ring or a 3-10 heterocyclic ring; wherein, said 3-10 discharged carbocylic ring or 3-10 heterocyclic ring is independently unsubstituted or substituted with one or more R S82 ;
  • n 7 is selected from 0, 1, 2, 3, 4, 5 or 6;
  • Ring M is selected from a 6-10 membered aryl ring or 5-10 membered heteroaryl containing 1, 2, 3 or 4 heteroatoms selected from N, O or S;
  • n 8 is selected from 0, 1, 2, 3, 4, 5 or 6;
  • two R S1 together with the carbon atom to which they are both attached form a 3-10 membered carbocyclic ring or a 3-10 heterocyclic ring; wherein, said 3-10 discharged carbocylic ring or 3-10 heterocyclic ring is independently unsubstituted or substituted with one or more R S11 ;
  • R S1 together with the atoms to which they are respectively attached form a 3-10 membered carbocyclic ring, a 3-10 membered heterocyclic ring, a 6-10 membered aryl ring or a 5-10 membered heteroaryl ring, wherein, each of rings is independently unsubstituted or substituted with one or more R S12 ;
  • n 1 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9;
  • R 3 is selected from
  • R 33 and R 34 together with the carbon atom to which they are both attached form a 3-10 membered carbocyclic ring or a 3-10 heterocyclic ring; wherein, said 3-10 discharged carbocylic ring or 3-10 heterocyclic ring is independently unsubstituted or substituted with one or more R S34 ;
  • R 38 and R 39 together with the carbon atom to which they are both attached form a 3-10 membered carbocyclic ring or a 3-10 heterocyclic ring; wherein, said 3-10 discharged carbocylic ring or 3-10 heterocyclic ring is independently unsubstituted or substituted with one or more R S310 ;
  • Ring D is selected from a 3-10 membered carbocyclic ring or a 3-10 membered heterocyclic ring;
  • R S31 together with the carbon atoms to which they are respectively attached form a 3-10 membered carbocyclic ring, a 3-10 membered heterocyclic ring, a 6-10 membered aryl ring or a 5-10 membered heteroaryl ring, wherein, each of rings is independently unsubstituted or substituted with one or more R S312 ;
  • two R S32 together with the carbon atom to which they are both attached form a 3-10 membered carbocyclic ring or a 3-10 heterocyclic ring; wherein, said 3-10 discharged carbocylic ring or 3-10 heterocyclic ring is independently unsubstituted or substituted with one or more R S321 ;
  • R 37 is selected from -N (R 37A ) 2 or 3-10 membered heterocyclyl, wherein said 3-10 membered heterocyclyl is optionally independently substituted with one or more R S37 ;
  • R S38 together with the carbon atoms to which they are respectively attached form a 3-10 membered carbocyclic ring, a 3-10 membered heterocyclic ring, a 6-10 membered aryl ring or a 5-10 membered heteroaryl ring, wherein, each of rings is independently unsubstituted or substituted with one or more R S382 ;
  • R S39 together with the carbon atoms to which they are respectively attached form a 3-10 membered carbocyclic ring, a 3-10 membered heterocyclic ring, a 6-10 membered aryl ring or a 5-10 membered heteroaryl ring, wherein, each of rings is independently unsubstituted or substituted with one or more R S392 ;
  • Ring E at each occurrence is selected from a 5-6 membered heteroaryl ring and ring F at each occurrence is a 3-10 membered heterocyclic ring when Z is selected from N;
  • Each of heteroaryl at each occurrence independently contains 1, 2, 3 or 4 heteroatoms selected from N, O, or S.
  • n 9 is selected from 0, 1, 2, 3, or 4.
  • R S8 is selected from deuterium, halogen, -C 1-6 alkyl, haloC 1-6 alkyl, haloC 1-6 alkoxy, -OH, -OC 1-6 alkyl, -CN, -NH 2 , -NH (C 1-6 alkyl) or -N (C 1-6 alkyl) 2 ; wherein, said -C 1-6 alkyl is independently unsubstituted or substituted with 1, 2, or 3 substituents slected from deuterium, halogen, haloC 1-6 alkyl, haloC 1-6 alkoxy, -CN, -NH 2 , -NH (C -NH (C -NH (C 1-6 alkyl) (C 1-6 alkyl) 2 ; wherein, said -C 1-6 alkyl is independently unsubstituted or substituted with 1, 2, or 3 substituents slected from deuterium, halogen, haloC 1-6 alkyl, hal
  • the moiety of is selected from:
  • R 1 is selected from hydrogen, halogen, -CN, -OC 1-6 alkyl, -O-haloC 1-6 alkyl, -S-haloC 1-6 alkyl, -C 1-6 alkyl or 3-6 membered cycloalkyl; said -OC 1-6 alkyl, -C 1-6 alkyl or 3-6 membered cycloalkyl is unsubsituted or substituted with 1, 2 or 3 substituents slected from deuterium, halogen, haloC 1-6 alkyl, haloC 1-6 alkoxy, -CN, -NH 2 , -NH (
  • m 81 is selected from 0, 1, 2, 3, 4, 5, 6, 7, or 8.
  • R S39 is selected from halogen
  • R S39 is selected from -F.
  • Ring B is a 4-6 membered heterocyclic ring containing the fused N atom.
  • two adjacent R S31 together with the carbon atoms to which they are respectively attached form a 5-10 membered heterocyclic ring containing 1 or 2 heteroatoms selected from N or O, a phenyl ring or a 5-10 membered heteroaryl ring containing 1 or 2 heteroatoms selected from N, O or S, wherein, each of rings is independently unsubstituted or substituted with 1, 2 or 3 R S312 .
  • Ring G is selected from a 5-6 membered heterocyclic ring containing 1 or 2 heteroatoms selected from N or O, a phenyl ring, a 5-6 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O, or S;
  • Ring H is selected from a 5-10 membered heterocyclic ring containing 1 or 2 heteroatoms selected from N or O, a phenyl ring, a 5-10 membered heteroaryl containing 1 or 2 heteroatoms selected from N, O, or S;
  • R S36 is same as R S31 ;
  • R S314 is selected from hydrogen or R S311 ;
  • n 31 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;
  • n 32 is selected from 0, 1, 2, 3, 4, 5, 6, 7 or 8;
  • m 33 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
  • m 34 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;
  • n 5 is selected from 0, 1, 2, 3, 4, 5, or 6;
  • n 6 is selected from 0, 1, 2, 3, 4, 5, or 6.
  • n 31 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;
  • n 32 is selected from 0, 1, 2, 3, 4, 5, 6, 7 or 8;
  • m 33 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
  • m 34 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;
  • n 5 is selected from 0, 1, 2, 3, 4, 5, or 6;
  • n 6 is selected from 0, 1, 2, 3, 4, 5, or 6.
  • R S311 is independently selected from deuterium, halogen, -C 1-6 alkyl, haloC 1-6 alkyl, haloC 1-6 alkoxy, -OH, -OC 1-6 alkyl, -CN, -NH 2 , -NH (C 1-6 alkyl) or -N (C 1-6 alkyl) 2 ; wherein, said -C 1-6 alkyl is independently unsubstituted or substituted with 1, 2, or 3 substituents slected from deuterium, halogen, haloC 1-6 alkyl, haloC 1-6 alkoxy, -CN, -NH 2 , -NH (C 1-6 alkyl) , -N (C 1-6 alkyl) 2 , -OH or -OC 1-6 alkly;
  • R S312 is independently selected from deuterium, halogen, -C 1-6 alkyl, haloC 1-6 alkyl, haloC 1-6 alkoxy, -OH, -OC 1-6 alkyl, -CN, -NH 2 , -NH (C 1-6 alkyl) or -N (C 1-6 alkyl) 2 ; wherein, said -C 1-6 alkyl is independently unsubstituted or substituted with 1, 2, or 3 substituents slected from deuterium, halogen, haloC 1-6 alkyl, haloC 1-6 alkoxy, -CN, -NH 2 , -NH (C 1-6 alkyl) , -N (C 1-6 alkyl) 2 , -OH or -OC 1-6 alkly;
  • R S314 is independently selected from hydrogen, deuterium, halogen, -C 1-6 alkyl, wherein, said -C 1-6 alkyl is independently unsubstituted or substituted with 1, 2, or 3 substituents slected from deuterium, halogen, haloC 1-6 alkyl, haloC 1-6 alkoxy, -CN, -NH 2 , -NH (C 1-6 alkyl) , -N (C 1-6 alkyl) 2 , -OH or -OC 1-6 alkly.
  • R S311 is independently selected from deuterium, -F or -OCH 3 ;
  • R S312 is independently selected from deuterium, -F, -OCH 3 , or -CH 2 OCH 3 ;
  • R S314 is independently selected from hydrogen, deuterium, -F, -CH 3 , -CH 2 OCH 3 , -CH 2 CH 2 CH 3 , -CH(CH 3 ) 2 , -CHF 2 , -CH 2 CH (CH 3 ) 2 .
  • n 31 is selected from 0 or 1;
  • n 32 is selected from 0 or 1;
  • m 33 is selected from 0 or 1;
  • n 34 is selected from 0 or 1;
  • m 5 is selected from 0 or 1;
  • n 6 is selected from 0 or 1.
  • the moiety of is selected from:
  • the moiety of is selected from:
  • the moiety of is selected from:
  • ring L is selected from a 4-6 membered heterocyclic ring optionally further comtaining 1 or 2 heteroatoms selected from N or O.
  • the moiety of is selected from:
  • R S315 is independently selected from deuterium, halogen, -C 1-6 alkyl, haloC 1-6 alkyl, haloC 1-6 alkoxy, -OH, -OC 1-6 alkyl, -CN, -NH 2 , -NH (C 1-6 alkyl) or -N (C 1-6 alkyl) 2 ; wherein, said -C 1-6 alkyl is independently unsubstituted or substituted with 1, 2, or 3 substituents slected from deuterium, halogen, haloC 1-6 alkyl, haloC 1-6 alkoxy, -CN, -NH 2 , -NH (C 1-6 alkyl) , -N (C 1-6 alkyl) 2 , -OH or -OC 1-6 alkly.
  • the moiety of is selected from:
  • the moiety of is selected from:
  • n 7 is selected from 0, 1, 2 or, 3;
  • R S4a is selected from -OH or -NH 2 ;
  • R S4b is selected from hydrogen, deuterium, halogen
  • R S4c is selected from hydrogen, deuterium, -C 1-3 alkyl, -C 2-3 alkenyl or -C 2-3 alkynyl;
  • R S4d is selected from hydrogen, deuterium or halogen
  • R S4e is selected from hydrogen, deuterium, halogen, -C 1-3 alkyl or haloC 1-3 alkyl;
  • R S4f is selected from -OH or -NH 2 ;
  • R S4g is selected from hydrogen, deuterium, halogen, -C 1-3 alkyl or haloC 1-3 alkyl;
  • R S4h is selected from hydrogen, deuterium, halogen, -C 1-3 alkyl or haloC 1-3 alkyl;
  • R S4i is selected from hydrogen, deuterium, halogen, -C 1-3 alkyl or haloC 1-3 alkyl;
  • R S4j is selected from hydrogen, deuterium, halogen, -CN, -C 1-3 alkyl, halogC 1-3 alkyl or -OhaloC 1-3 alkyl;
  • R S4k is selected from hydrogen, deuterium, halogen, -CN, -C 1-3 alkyl, halogC 1-3 alkyl or -OhaloC 1-3 alkyl;
  • R S4l is selected from hydrogen, deuterium, halogen, -CN, -C 1-3 alkyl, halogC 1-3 alkyl or -OhaloC 1-3 alkyl;
  • R S4m is selected from hydrogen, deuterium, halogen, -CN, -C 1-3 alkyl, halogC 1-3 alkyl or -OhaloC 1-3 alkyl.
  • n 7 is selected from 0;
  • R S4a is selected from -OH or -NH 2 ;
  • R S4b is selected from -F
  • R S4c is selected from ethyl, ethenyl or ethynyl
  • R S4d is selected from hydrogen, or -F;
  • R S4e is selected from -F
  • R S4f is selected from -NH 2 ;
  • R S4g is selected from hydrogen, -F, or methyl
  • R S4h is selected from hydrogen, -F or methyl
  • R S4i is selected from -I or -CF 3 ;
  • R S4j is selected from -CN
  • R S4k is selected from hydrogen
  • R S4l is selected from methyl
  • R S4m is selected from -OCF 2 Cl, -OCF 3 or -CF 2 H.
  • R 4 is selected from
  • R 4 is selected from
  • R 6 is selected from hydrogen, deuterium, halogen, -C 1-6 alkyl, -C 2-6 alkenyl, -C 2-6 alkynyl, -OH, -OC 1-6 alkyl, -NH 2 , -NHC 1-6 alkyl, -N (C 1-6 alkyl) 2 , or 3-10 membered cycloalkyl; wherein said -C 1-6 alkyl, -C 2-6 alkenyl, -C 2-6 alkynyl, -OH, -OC 1-6 alkyl, -NH 2 , -NHC 1-6 alkyl, -N
  • R 6 is selected from hydrogen, -F, -OCH 3 , -OCH 2 CH 3 , -NHCH 3 ,
  • R 4 is selected from
  • R 5 is selected from -F
  • R 6 is selected from
  • the compound is selected from the following formulas:
  • R 4 is selected from:
  • the compound is selected from the following formulas:
  • R 4 is selected from:
  • R 6 is selected from:
  • R 7 is selected from:
  • the compound is selected from the following formulas:
  • R 4 is selected from:
  • R 6 is selected from:
  • R 7 is selected from:
  • the compound is selected from the following formulas:
  • R 1 and R 6 are independently selected from:
  • R 4 is selected from:
  • R 3 , R 5 , R 6 , R 7 , R 81 , R 82 , X 2 , Y 1 , R S1 , R S8 , m 1 , n 7 , n 8 and ring M have the same definitions as above;
  • R 41 at each occurrence is independently selected from
  • R 4c is selected from hydrogen, -C 1-30 alkyl, -C 2-30 alkenyl, -C 2-30 alkynyl, -C 0-6 alkylene- (3-20 membered carbocyclyl) , -C 0-6 alkylene- (3-20 membered heterocyclyl) , -C 0-6 alkylene- (6-10 membered aryl) or -C 0-6 alkylene- (5-10 membered heteroaryl) , each of which is independently substituted with one or more R 4j ;
  • -OR 41 is selected from:
  • a pharmaceutical composition comprising a therapeutically effective amount of the compound of formula (I) or formula (II) , a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof, a prodrug thereof, a deuterated molecule thereof or a PROTAC molecule thereof of any one of [1] to [86] , and a pharmaceutically acceptable excipient.
  • a method for treating cancer in a subject comprising administering a therapeutically effective amount of a compound of formula (I) or formula (II) , a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof, a prodrug thereof, a deuterated molecule thereof or a PROTAC molecule thereof of any one of [1] to [86] , or the pharmaceutical composition of [87] to a subject in need thereof.
  • a method for treating cancer in a subject in need thereof comprising:
  • the cancer is associated with at least one of K-Ras G12C, K-Ras G12D, K-Ras G12V, K-Ras G13D, K-Ras G12R, K-Ras G12S, K-Ras G12A, K-Ras Q61H mutation and/or K-Ras wild type amplification.
  • halogen or “halo” , as used herein, unless otherwise indicated, means fluoro, chloro, bromo or iodo.
  • the preferred halogen groups include -F, -Cl and -Br.
  • alkyl as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight or branched.
  • -C 1-6 alkyl radicals include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, 3- (2-methyl) butyl, 2-pentyl, 2-methylbutyl, neopentyl, n-hexyl, 2-hexyl and 2-methylpentyl.
  • C 1-3 as in C 1-3 alkyl is defined to identify the group as having 1, 2, 3, 4, 5 or 6 carbon atoms in a linear or branched arrangement.
  • haloalkyl such as -C 1-6 haloalkyl, -C 1-4 haloalkyl or -C 1-3 haloalkyl
  • an alkyl chain such as -C 1-6 alkyl, -C 1-4 alkyl or -C 1-3 alkyl
  • examples include trifluoromethyl, difluoromethyl and fluoromethyl.
  • alkylene means a difunctional group obtained by removal of a hydrogen atom from an alkyl group defined above.
  • methylene i.e., -CH 2 -
  • ethylene i.e., -CH 2 -CH 2 -or -CH (CH 3 ) -
  • propylene i.e., -CH 2 -CH 2 -CH 2 -, -CH (-CH 2 -CH 3 ) -or -CH 2 -CH (CH 3 ) -
  • alkenyl means a straight or branch-chained hydrocarbon radical containing one or more double bonds and typically from 2 to 20 carbon atoms in length.
  • C 2-6 alkenyl contains from 2 to 6 carbon atoms.
  • Alkenyl group include, but are not limited to, for example, ethenyl, propenyl, butenyl, 2-methyl-2-buten-1-yl, hepetenyl, octenyl and the like.
  • alkynyl contains a straight or branch-chained hydrocarbon radical containing one or more triple bonds and typically from 2 to 20 carbon atoms in length.
  • C 2-6 alkynyl contains from 2 to 6 carbon atoms.
  • Representative alkynyl groups include, but are not limited to, for example, ethynyl, 1-propynyl, 1-butynyl, heptynyl, octynyl and the like.
  • alkoxy radicals are oxygen ethers formed from the previously described alkyl groups.
  • aryl refers to an unsubstituted or substituted mono or polycyclic aromatic ring system containing carbon ring atoms.
  • the preferred aryls are mono cyclic or bicyclic 6-10 membered aromatic ring systems. Phenyl and naphthyl are preferred aryls.
  • heterocyclic refers to unsubstituted and substituted mono or polycyclic non-aromatic ring system containing one or more heteroatoms, which comprising moncyclic heterocyclic ring, bicyclic heterocyclic ring, bridged heterocyclic ring, fused heterocyclic ring or sipro heterocyclic ring.
  • Preferred heteroatoms include N, O, and S, including N-oxides, sulfur oxides, and dioxides.
  • the ring is three to ten membered and is either fully saturated or has one or more degrees of unsaturation. Multiple degrees of substitution, preferably one, two or three, are included within the present definition.
  • heterocyclic groups include, but are not limited to azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, oxopiperazinyl, oxopiperidinyl, oxoazepinyl, azepinyl, tetrahydrofuranyl, dioxolanyl, tetrahydroimidazolyl, tetrahydrothiazolyl, tetrahydrooxazolyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, thiamorpholinylsulfoxide, thiamorpholinylsulfone and oxadiazolyl.
  • heteroaryl represents an aromatic ring system containing carbon (s) and at least one heteroatom.
  • Heteroaryl may be monocyclic or polycyclic, substituted or unsubstituted.
  • a monocyclic heteroaryl group may have 1 to 4 heteroatoms in the ring, while a polycyclic heteroaryl may contain 1 to 10 hetero atoms.
  • a polycyclic heteroaryl ring may contain fused, spiro or bridged ring junction, for example, bycyclicheteroaryl is a polycyclic heteroaryl.
  • Bicyclic heteroaryl rings may contain from 8 to 12 member atoms.
  • Monocyclic heteroaryl rings may contain from 5 to 8 member atoms (cabons and heteroatoms) .
  • heteroaryl groups include, but are not limited to thienyl, furanyl, imidazolyl, isoxazolyl, oxazolyl, pyrazolyl, pyrrolyl, thiazolyl, thiadiazolyl, triazolyl, pyridyl, pyridazinyl, indolyl, azaindolyl, indazolyl, benzimidazolyl, benzofuranyl, benzothienyl, benzisoxazolyl, benzoxazolyl, benzopyrazolyl, benzothiazolyl, benzothiadiazolyl, benzotriazolyladeninyl, quinolinyl or isoquinolinyl.
  • cycloalkyl refers to a substituted or unsubstituted monocyclic ring, bicyclic ring, bridged ring, fused ring, sipiro ring non-aromatic ring system only containing carbon atoms.
  • Examplary “cycloalkyl” groups includes but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and so on.
  • composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts. Accordingly, pharmaceutical compositions containing the compounds of the present invention as the active ingredient as well as methods of preparing the instan
  • pharmaceutically acceptable salts refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids.
  • the compound of the present invention is acidic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic bases, including inorganic bases and organic bases.
  • the compound of the present invention is basic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Since the compounds in the present invention are intended for pharmaceutical use they are preferably provided in substantially pure form, for example at least 60%pure, more suitably at least 75%pure, especially at least 98%pure (%are on a weight for weight basis) .
  • the present invention includes within its scope the prodrugs of the compounds of this invention.
  • such prodrugs will be functional derivatives of the compounds that are readily converted in vivo into the required compound.
  • the term “administering” shall encompass the treatment of the various disorders described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo after administration to the subject.
  • Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs” , ed. H. Bundgaard, Elsevier, 1985.
  • the present invention includes compounds described can contain one or more asymmetric centers and may thus give rise to diastereomers and optical isomers.
  • the present invention includes all such possible diastereomers as well as their racemic mixtures, their substantially pure resolved enantiomers, all possible geometric isomers, and pharmaceutically acceptable salts thereof.
  • the present invention includes all stereoisomers of the compound and pharmaceutically acceptable salts thereof. Further, mixtures of stereoisomers as well as isolated specific stereoisomers are also included. During the course of the synthetic procedures used to prepare such compounds or in using racemization or epimerization procedures known to those skilled in the art, the products of such procedures can be a mixture of stereoisomers.
  • stereoisomer refers to an isomer in which atoms or groups of atoms in the molecule are connected to each other in the same order but differ in spatial arrangement, including conformational isomers and conformational isomers.
  • the configuration isomers include geometric isomers and optical isomers, and optical isomers mainly include enantiomers and diastereomers.
  • the invention includes all possible stereoisomers of the compound.
  • Certain of the compounds provided herein may exist as atropisomers, which are conformational stereoisomers that occur when rotation about a single bond in the molecule is prevented, or greatly slowed, as a result of steric interactions with other parts of the molecule.
  • the compounds provided herein include all atropisomers, both as pure individual atropisomer preparations, enriched preparations of each, or a non-specific mixture of each. Where the rotational barrier about the single bond is high enough, and interconversion between conformations is slow enough, separation and isolation of the isomeric species may be permitted.
  • the present invention is intended to include all isotopes of atoms occurring in the present compounds.
  • Isotopes include those atoms having the same atomic number but different mass numbers.
  • isotopes of hydrogen include deuterium and tritium.
  • the isotopes of hydrogen can be denoted as 1 H (hydrogen) , 2 H (deuterium) and 3 H (tritium) . They are also commonly denoted as D for deuterium and T for tritium.
  • CD 3 denotes a methyl group wherein all of the hydrogen atoms are deuterium.
  • Isotopes of carbon include 13 C and 14 C.
  • Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by prcesses analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent.
  • the present invention includes any possible tautomers and pharmaceutically acceptable salts thereof, and mixtures thereof, except where specifically stated otherwise.
  • the present invention includes any possible solvates and polymorphic forms.
  • a type of a solvent that forms the solvate is not particularly limited so long as the solvent is pharmacologically acceptable.
  • compositions of the present invention comprise a compound in present invention (or a pharmaceutically acceptable salt thereof) as an active ingredient, a pharmaceutically acceptable carrier and optionally other therapeutic ingredients or adjuvants.
  • the compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered.
  • the pharmaceutical compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.
  • the compounds in present invention or a prodrug or a metabolite or pharmaceutically acceptable salts thereof, of this invention can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier of conventional pharmaceutical compounding techniques.
  • the carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g. oral or parenteral (including intravenous) .
  • the pharmaceutical compositions of the present invention can be presented as discrete units suitable for oral administration such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient.
  • compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in-water emulsion or as a water-in-oil liquid emulsion.
  • the compound represented by Formula I or a pharmaceutically acceptable salt thereof may also be administered by controlled release means and/or delivery devices.
  • the compositions may be prepared by any of the methods of pharmacy. In general, such methods include a step of bringing into association the active ingredient with the carrier that constitutes one or more necessary ingredients.
  • the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both. The product can then be conveniently shaped into the desired presentation.
  • compositions of this invention may include a pharmaceutically acceptable carrier and a compound or a pharmaceutically acceptable salt.
  • the compounds of Formula I or pharmaceutically acceptable salts thereof, can also be included in pharmaceutical compositions in combination with one or more other therapeutically active compounds.
  • the pharmaceutical carrier employed can be, for example, a solid, liquid or gas.
  • solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid.
  • liquid carriers are sugar syrup, peanut oil, olive oil, and water.
  • gaseous carriers include carbon dioxide and nitrogen.
  • oral liquid preparations such as suspensions, elixirs and solutions
  • carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be used to form oral solid preparations such as powders, capsules and tablets.
  • oral solid preparations such as powders, capsules and tablets.
  • tablets and capsules are the preferred oral dosage units whereby solid pharmaceutical carriers are employed.
  • tablets may be coated by standard aqueous or nonaqueous techniques.
  • a tablet containing the composition of this invention may be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants.
  • Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent.
  • Each tablet preferably contains from about 0.05mg to about 5g of the active ingredient and each cachet or capsule preferably containing from about 0.05mg to about 5g of the active ingredient.
  • a formulation intended for the oral administration to humans may contain from about 0.5mg to about 5g of active agent, compounded with an appropriate and convenient amount of carrier material which may vary from about 0.05 to about 95 percent of the total composition.
  • Unit dosage forms will generally contain between from about 0.0lmg to about 2g of the active ingredient, typically 0.01mg, 0.02mg, 1mg, 2mg, 3mg, 4mg, 5mg, 6mg, 7mg, 8mg, 9mg, 10mg, 25mg, 50mg, l00mg, 200mg, 300mg, 400mg, 500mg, 600mg, 800mg, l000mg, 1500mg or 2000mg.
  • compositions of the present invention suitable for parenteral administration may be prepared as solutions or suspensions of the active compounds in water.
  • a suitable surfactant can be included such as, for example, hydroxypropylcellulose.
  • Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms.
  • compositions of the present invention suitable for injectable use include sterile aqueous solutions or dispersions.
  • the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions.
  • the final injectable form must be sterile and must be effectively fluid for easy syringability.
  • the pharmaceutical compositions must be stable under the conditions of manufacture and storage; thus, preferably should be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol) , vegetable oils, and suitable mixtures thereof.
  • compositions of the present invention can be in a form suitable for topical use such as, for example, an aerosol, cream, ointment, lotion, dusting powder or the like. Further, the compositions can be in a form suitable for use in transdermal devices. These formulations may be prepared, utilizing a compound represented by Formula I of this invention or a pharmaceutically acceptable salt thereof, via conventional processing methods. As an example, a cream or ointment is prepared by admixing hydrophilic material and water, together with about 0.05wt%to about 10wt%of the compound, to produce a cream or ointment having a desired consistency.
  • compositions of this invention can be in a form suitable for rectal administration wherein the carrier is a solid. It is preferable that the mixture forms unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art. The suppositories may be conveniently formed by first admixing the composition with the softened or melted carrier (s) followed by chilling and shaping in molds.
  • the pharmaceutical formulations described above may include, as appropriate, one or more additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.
  • additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.
  • additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.
  • additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.
  • other adjuvants can be included to render the formulation isotonic with the blood of the intended recipient.
  • dosage levels on the order of from about 0.001mg/kg to about 150mg/kg of body weight per day are useful in the treatment of the above-indicated conditions or alternatively about 0.05mg to about 7g per patient per day.
  • inflammation, cancer, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system (CNS) may be effectively treated by the administration of from about 0.001 to 50mg of the compound per kilogram of body weight per day or alternatively about 0.05mg to about 3.5g per patient per day.
  • the compound in the present invention could be synthesized and the activity could be tested according to the pharmacological experiments.
  • the intermediates were synthesized using conventional preparation method.
  • Compound 8A-3 Compound 8A-3 was synthesized according to the steps of Compound 1A-4; 0.26 g, 843.80 ⁇ mol) in dioxane (10 mL) and DIEA (0.30 g, 2.32 mmol) was stirred at 100 °C for 18 hours under nitrogen atmosphere. Then the mixture was quenched with water (30 mL) , extracted with EA (2 ⁇ 30 mL) , the organic layer was dried over anhydrous Na 2 SO 4 , filtrated and concentrated in vacuum.
  • Compound 8B, Compound 8C, Compound 8D was synthesized according to the steps of Compound 8A.
  • GDP-loaded HIS-KRAS (G12V, aa 1-169) was pre-incubated with a compound in the presence of 10nM GDP in a 384-well plate (Greiner) for 15 min, then purified SOS1 ExD (Flag tag, aa 564-1049) , BODIPY TM FL GTP (Invitrogen) and MAb (monoclonal antibody) Anti 6HIS-Tb cryptate Gold (Cisbio) were added to the assay wells (Final concentration: 10-15nM GDP-loaded HIS-KRAS (G12V) , 5 nM GDP, 0.5 ⁇ M SOS1 ExD, 80 nM BODIPY TM FL GTP, 52.5 ng/mL MAb Anti 6HIS-Tb cryptate Gold) and incubated for 4 hours at 25 °C.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des inhibiteurs de protéines mutantes KRAS de formule (I) ou de formule (II), une composition les contenant et leur utilisation.
PCT/CN2023/101393 2022-06-20 2023-06-20 Inhibiteurs de protéine mutante k-ras WO2023246777A1 (fr)

Applications Claiming Priority (26)

Application Number Priority Date Filing Date Title
CNPCT/CN2022/099737 2022-06-20
CN2022099737 2022-06-20
CNPCT/CN2022/103289 2022-07-01
CN2022103289 2022-07-01
CNPCT/CN2022/113757 2022-08-19
CN2022113757 2022-08-19
CN2022120979 2022-09-23
CNPCT/CN2022/120979 2022-09-23
CN2022121305 2022-09-26
CNPCT/CN2022/121305 2022-09-26
CNPCT/CN2022/121646 2022-09-27
CN2022121646 2022-09-27
CN2022123189 2022-09-30
CNPCT/CN2022/123189 2022-09-30
CN2022125527 2022-10-14
CNPCT/CN2022/125527 2022-10-14
CNPCT/CN2022/126762 2022-10-21
CN2022126762 2022-10-21
CN2022127364 2022-10-25
CNPCT/CN2022/127364 2022-10-25
CN2022137989 2022-12-09
CNPCT/CN2022/137989 2022-12-09
CN2023094187 2023-05-15
CNPCT/CN2023/094187 2023-05-15
CN2023098440 2023-06-06
CNPCT/CN2023/098440 2023-06-06

Publications (1)

Publication Number Publication Date
WO2023246777A1 true WO2023246777A1 (fr) 2023-12-28

Family

ID=89379157

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/101393 WO2023246777A1 (fr) 2022-06-20 2023-06-20 Inhibiteurs de protéine mutante k-ras

Country Status (1)

Country Link
WO (1) WO2023246777A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024179546A1 (fr) * 2023-03-01 2024-09-06 Ascentage Pharma (Suzhou) Co., Ltd. Inhibiteurs de kras
WO2024206858A1 (fr) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions pour induire une hydrolyse de ras gtp et leurs utilisations

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062209A2 (fr) * 2002-01-17 2003-07-31 Neurogen Corporation Analogues de quinazoline-4-ylamine substitues
WO2020108613A1 (fr) * 2018-11-30 2020-06-04 江苏豪森药业集团有限公司 Dérivés hétéroaromatiques destinés à être utilisés comme régulateurs, leur procédé de préparation et leur utilisation
CN113754653A (zh) * 2020-06-05 2021-12-07 明慧医药（上海）有限公司 一种kras g12c抑制剂化合物及其用途
WO2022002118A1 (fr) * 2020-07-01 2022-01-06 四川海思科制药有限公司 Dérivé hétérocyclique à cycles fusionnés et son utilisation médicale
WO2022031678A1 (fr) * 2020-08-04 2022-02-10 Mirati Therapeutics, Inc. Inhibiteurs de kras g12d
WO2022105855A1 (fr) * 2020-11-20 2022-05-27 Jacobio Pharmaceuticals Co., Ltd. Inhibiteurs de kras g12d
WO2022132200A1 (fr) * 2020-12-15 2022-06-23 Mirati Therapeutics, Inc. Inhibiteurs pan-kras d'azaquinazoline
WO2022177917A2 (fr) * 2021-02-16 2022-08-25 Theras, Inc. Compositions et procédés d'inhibition de ras
WO2022247760A1 (fr) * 2021-05-22 2022-12-01 上海科州药物研发有限公司 Composés hétérocycliques utiles en tant qu'inhibiteurs de kras, leur préparation et leur utilisation thérapeutique
WO2022248885A2 (fr) * 2021-05-28 2022-12-01 Redx Pharma Plc. Composés
WO2023004102A2 (fr) * 2021-07-23 2023-01-26 Theras, Inc. Compositions et procédés d'inhibition de ras
WO2023020518A1 (fr) * 2021-08-18 2023-02-23 Jacobio Pharmaceuticals Co., Ltd. Dérivés de n-cyclopropylpyrido [4, 3-d] pyrimidin-4-amine et leurs utilisations
WO2023020521A1 (fr) * 2021-08-18 2023-02-23 Jacobio Pharmaceuticals Co., Ltd. Dérivés de pyrimidine fusionnée avec la pyridine et leur utilisation
WO2023061294A1 (fr) * 2021-10-13 2023-04-20 再鼎医药(上海)有限公司 Régulateur dérivé hétérocyclique contenant de l'azote, son procédé de préparation et son utilisation
WO2023081840A1 (fr) * 2021-11-05 2023-05-11 Frontier Medicines Corporation Inhibiteurs de kras g12c

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062209A2 (fr) * 2002-01-17 2003-07-31 Neurogen Corporation Analogues de quinazoline-4-ylamine substitues
WO2020108613A1 (fr) * 2018-11-30 2020-06-04 江苏豪森药业集团有限公司 Dérivés hétéroaromatiques destinés à être utilisés comme régulateurs, leur procédé de préparation et leur utilisation
CN113754653A (zh) * 2020-06-05 2021-12-07 明慧医药（上海）有限公司 一种kras g12c抑制剂化合物及其用途
WO2022002118A1 (fr) * 2020-07-01 2022-01-06 四川海思科制药有限公司 Dérivé hétérocyclique à cycles fusionnés et son utilisation médicale
WO2022031678A1 (fr) * 2020-08-04 2022-02-10 Mirati Therapeutics, Inc. Inhibiteurs de kras g12d
WO2022105855A1 (fr) * 2020-11-20 2022-05-27 Jacobio Pharmaceuticals Co., Ltd. Inhibiteurs de kras g12d
WO2022132200A1 (fr) * 2020-12-15 2022-06-23 Mirati Therapeutics, Inc. Inhibiteurs pan-kras d'azaquinazoline
WO2022177917A2 (fr) * 2021-02-16 2022-08-25 Theras, Inc. Compositions et procédés d'inhibition de ras
WO2022247760A1 (fr) * 2021-05-22 2022-12-01 上海科州药物研发有限公司 Composés hétérocycliques utiles en tant qu'inhibiteurs de kras, leur préparation et leur utilisation thérapeutique
WO2022248885A2 (fr) * 2021-05-28 2022-12-01 Redx Pharma Plc. Composés
WO2023004102A2 (fr) * 2021-07-23 2023-01-26 Theras, Inc. Compositions et procédés d'inhibition de ras
WO2023020518A1 (fr) * 2021-08-18 2023-02-23 Jacobio Pharmaceuticals Co., Ltd. Dérivés de n-cyclopropylpyrido [4, 3-d] pyrimidin-4-amine et leurs utilisations
WO2023020521A1 (fr) * 2021-08-18 2023-02-23 Jacobio Pharmaceuticals Co., Ltd. Dérivés de pyrimidine fusionnée avec la pyridine et leur utilisation
WO2023061294A1 (fr) * 2021-10-13 2023-04-20 再鼎医药(上海)有限公司 Régulateur dérivé hétérocyclique contenant de l'azote, son procédé de préparation et son utilisation
WO2023081840A1 (fr) * 2021-11-05 2023-05-11 Frontier Medicines Corporation Inhibiteurs de kras g12c

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE Registry CAS; 15 March 2023 (2023-03-15), ANONYMOUS : ".", XP093121243, retrieved from STN Database accession no. 2911541-90-5 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024179546A1 (fr) * 2023-03-01 2024-09-06 Ascentage Pharma (Suzhou) Co., Ltd. Inhibiteurs de kras
WO2024206858A1 (fr) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions pour induire une hydrolyse de ras gtp et leurs utilisations

Similar Documents

Publication Publication Date Title
WO2022188729A1 (fr) Dérivés cycliques fusionnés utiles en tant qu'inhibiteurs de kras g12d
WO2021185233A1 (fr) Inhibiteurs de protéine mutante kras
WO2022105855A1 (fr) Inhibiteurs de kras g12d
EP3584239B1 (fr) Composé contenant un alcynyle o-aminohétéroaryle, son procédé de préparation et son utilisation
CN108349981B (zh) 新型的吡唑并[3，4－d]嘧啶化合物或其盐
TWI711619B (zh) 作爲蛋白質激酶抑制劑之胺基噠嗪酮化合物
WO2023246777A1 (fr) Inhibiteurs de protéine mutante k-ras
CN112341457A (zh) Kras突变蛋白抑制剂
EP3173412B1 (fr) Dérivé 7h-pyrrolo[2,3-d]pyrimidine 2,4-disubstituté, procédé de préparation et utilisation médicinale de ce dernier
WO2021057832A1 (fr) Inhibiteur de protéine mutante kras
WO2018196677A1 (fr) Dérivé de fluoroallylamine et son utilisation
US20070232669A1 (en) N-phenylbenzotriazolyl c-kit inhibitors
EP2625176B1 (fr) Composés substitués de 6-amino-pyridazin-3-yle carboxamide comme modulateurs de protéine kinases
WO2024041621A1 (fr) Inhibiteurs de protéines mutantes k-ras
US12103929B2 (en) Tricyclic compounds
CN115702145A (zh) 用于治疗炎性疾病的取代的吡啶
WO2022156708A1 (fr) Inhibiteur d'enzyme parp7
WO2023041055A1 (fr) Inhibiteur de kif18a
WO2018019252A1 (fr) Nouveaux dérivés de pyridine fusionnés utiles en tant qu'inhibiteurs de la kinase fak/aurora
WO2020147702A1 (fr) Inhibiteurs d'egfr, compositions et procédés associés
WO2022188889A1 (fr) Composé utile en tant qu'inhibiteur de parp7
TWI780077B (zh) 噻吩並嘧啶類化合物、其製備方法、藥用組合物及其應用
WO2024008068A1 (fr) Inhibiteurs de protéine mutante k-ras
CN115803325A (zh) 一种egfr抑制剂及其制备方法和应用
WO2022170947A1 (fr) Dérivés de tétrahydronaphtyridine utilisés en tant qu'inhibiteurs de g12c mutants kras, leur procédé de préparation et leur utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23826424

Country of ref document: EP

Kind code of ref document: A1